Drug intelligence / Profile preview

NVC-001B

Development stage: Unknown
Lead developer: Nuevocor
Modality: Gene Therapies

Overview

NVC-001B is a pipeline asset under development by Nuevocor, a biotechnology company focused on developing gene therapies for cardiomyopathies. While Nuevocor's lead candidate, NVC-001, is an AAV-based gene therapy designed to address LMNA-related dilated cardiomyopathy by restoring nuclear envelope integrity and reducing mechanical stress on the nucleus, the specific indication and mechanism of action for NVC-001B remain undisclosed. It is categorized as one of Nuevocor's pathway-specific genetic medicines in preclinical development.

Beyond the preview

Go deeper on NVC-001B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NVC-001B.

Explore the full profile